Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages

Liu, Zhipeng, Xie, Yue, Xiong, Yao, Liu, Siliang, Qiu, Chen, Zhu, Zhenhao, Mao, Hua, Yu, Meng, Wang, Xinying · 2020 · Cancer Letters

Abstract

Resistance to oxaliplatin is a major obstacle hindering the clinical treatment of colorectal cancer, but the underlying immunological mechanism has not yet been well illustrated. As a pivotal immunosuppressive component in tumor microenvironment, myeloid-derived suppressor cells (MDSCs) and their differentiated tumor-associated macrophages (TAMs) have been considered to be associated with resistance to chemotherapy. The aim of current study was to investigate the role of MDSCs in oxaliplatin-resistance and antitumor activity in colorectal cancer. Here, we found that tumor-bearing mice treated with oxaliplatin performed remarkably decreasing M-MDSCs and M1-type TAMs differentiated from MDSCs in tumor site, which inspired us to combine immunotherapy that activates M1-like TAMs to conquer oxaliplatin resistance. In addition, this study further confirmed a dose-dependent improvement of M1-like macrophage supernatants on enhancing pro-apoptotic effect and inhibiting migration and invasion of cancer cells incubated with oxaliplatin. Administration of oxaliplatin combined with Toll-like receptors agonists R848 reversed the functional orientation of MDSCs towards M1-like macrophages and strengthened antitumor effect of oxaliplatin. In this study, we uncovered novel immunological mechanism of oxaliplatin-resistance and showed the great potential of TLR7/8 agonist as a new immunologic adjuvant in chemotherapy for oxaliplatin-resistant colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2019.10.020

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 45

  1. Benson, 2018, NCCN guidelines insights: colon cancer, version 2.2018, J. Natl. Compr. Cancer Netw.: J. Natl. Compr. Cancer Netw., 16, 359, 10.6004/jnccn.2018.0021 · DOI · Paper page
  2. Schmoll, 2014, Lancet Oncol., 15, 1481, 10.1016/S1470-2045(14)70486-3 · DOI · Paper page
  3. Shah, 2016, Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database, J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol., 34, 843, 10.1200/JCO.2015.63.0558 · DOI · Paper page
  4. Crea, 2011, Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies, Drug Resist. Updates : Rev. Comment. Antimicrob. Anticancer Chemother., 14, 280, 10.1016/j.drup.2011.08.001 · DOI
  5. Martinez-Balibrea, 2015, Tumor-related molecular mechanisms of oxaliplatin resistance, Mol. Cancer Ther., 14, 1767, 10.1158/1535-7163.MCT-14-0636 · DOI · Paper page
  6. Feng, 2019, Immunomodulatory nanosystems, Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany), 6, 1900101
  7. Duan, 2019, Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors, Nat. Commun., 10, 1899, 10.1038/s41467-019-09221-x · DOI · Paper page
  8. Li, 2018, Polymer nanoparticles as adjuvants in cancer immunotherapy, Nano Res., 11, 5769, 10.1007/s12274-018-2124-7 · DOI
  9. Yu, 2019, Recent advances in delivery of photosensitive metal-based drugs, Coord. Chem. Rev., 387, 154, 10.1016/j.ccr.2019.01.020 · DOI
  10. Xiao, 2018, Recent progress in polymer-based platinum drug delivery systems, Prog. Polym. Sci., 87, 10.1016/j.progpolymsci.2018.07.004 · DOI · Paper page
  11. Baretti, 2018, The role of epigenetic therapies in colorectal cancer, Curr. Probl. Cancer, 42, 530, 10.1016/j.currproblcancer.2018.03.001 · DOI
  12. Feng, 2018, Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment, Adv. Mater. (Deerfield Beach, Fla.), 30, 10.1002/adma.201803001 · DOI · Paper page
  13. Singh, 2009, Nanoparticle-based targeted drug delivery, Exp. Mol. Pathol., 86, 215, 10.1016/j.yexmp.2008.12.004 · DOI · Paper page
  14. Hui, 2015, Tumor microenvironment: sanctuary of the devil, Cancer Lett., 368, 7, 10.1016/j.canlet.2015.07.039 · DOI · Paper page
  15. Yang, 2017, IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer, Oncogene, 36, 2969, 10.1038/onc.2016.448 · DOI
  16. Kumar, 2016, The nature of myeloid-derived suppressor cells in the tumor microenvironment, Trends Immunol., 37, 208, 10.1016/j.it.2016.01.004 · DOI · Paper page
  17. Veglia, 2018, Myeloid-derived suppressor cells coming of age, Nat. Immunol., 19, 108, 10.1038/s41590-017-0022-x · DOI · Paper page
  18. Hamilton, 2014, Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas, J. Immunol. (Baltimore, Md.: 1950), 192, 512, 10.4049/jimmunol.1300096 · DOI
  19. Gonzalez, 2018, Roles of the immune system in cancer: from tumor initiation to metastatic progression, Genes Dev., 32, 1267, 10.1101/gad.314617.118 · DOI · Paper page
  20. Henze, 2016, The impact of hypoxia on tumor-associated macrophages, J. Clin. Investig., 126, 3672, 10.1172/JCI84427 · DOI · Paper page
  21. Espagnolle, 2014, Specific inhibition of the VEGFR-3 tyrosine kinase by SAR131675 reduces peripheral and tumor associated immunosuppressive myeloid cells, Cancers, 6, 472, 10.3390/cancers6010472 · DOI
  22. Porta, 2015, Molecular and epigenetic basis of macrophage polarized activation, Semin. Immunol., 27, 237, 10.1016/j.smim.2015.10.003 · DOI · Paper page
  23. Yin, 2013, Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation, Cancer Immunol. Res., 1, 256, 10.1158/2326-6066.CIR-13-0073 · DOI
  24. Gonzalez-Aparicio, 2011, Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice, Gut, 60, 341, 10.1136/gut.2010.211722 · DOI
  25. Shimizu, 2017, Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model, Cancer Sci., 108, 1864, 10.1111/cas.13305 · DOI
  26. Widmer, 2018, Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation, Int. J. Pharm., 535, 444, 10.1016/j.ijpharm.2017.11.031 · DOI
  27. Pilch, 2018, Antitumor activity of TLR7 is potentiated by CD200R antibody leading to changes in the tumor microenvironment, Cancer Immunol. Res., 6, 930, 10.1158/2326-6066.CIR-17-0454 · DOI
  28. Spinetti, 2016, TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function, OncoImmunology, 5, 10.1080/2162402X.2016.1230578 · DOI
  29. Cheadle, 2017, A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells, Leukemia, 31, 1611, 10.1038/leu.2016.352 · DOI
  30. Dovedi, 2013, Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma, Blood, 121, 251, 10.1182/blood-2012-05-432393 · DOI
  31. Lee, 2014, Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells, Arch Pharm. Res. (Seoul), 37, 1234, 10.1007/s12272-014-0379-4 · DOI
  32. Wang, 2015, Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells, J. Immunol. (Baltimore, Md.: 1950), 194, 4215, 10.4049/jimmunol.1402004 · DOI
  33. Okuma, 2017, p16(Ink4a) and p21(Cip1/Waf1) promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis, Nat. Commun., 8, 2050, 10.1038/s41467-017-02281-x · DOI · Paper page
  34. Liu, 2015, Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway, Immunology, 146, 379, 10.1111/imm.12508 · DOI
  35. Bayik, 2018, Factors influencing the differentiation of human monocytic myeloid-derived suppressor cells into inflammatory macrophages, Front. Immunol., 9, 608, 10.3389/fimmu.2018.00608 · DOI
  36. Diaz-Montero, 2009, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy, Cancer Immunol. Immunother. CII, 58, 49, 10.1007/s00262-008-0523-4 · DOI · Paper page
  37. Kanterman, 2014, Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes, Cancer Res., 74, 6022, 10.1158/0008-5472.CAN-14-0657 · DOI · Paper page
  38. Limagne, 2016, Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen, Cancer Res., 76, 5241, 10.1158/0008-5472.CAN-15-3164 · DOI · Paper page
  39. Kweekel, 2005, Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy, Cancer Treat Rev., 31, 90, 10.1016/j.ctrv.2004.12.006 · DOI · Paper page
  40. Roberts, 2018, Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction, J. Neuro Oncol., 140, 497, 10.1007/s11060-018-2979-1 · DOI
  41. Fujimura, 2018, Tumor-associated macrophages: therapeutic targets for skin cancer, Front. Oncol., 8, 3, 10.3389/fonc.2018.00003 · DOI
  42. Li, 2017, Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway, Acta Biochim. Biophys. Sin., 49, 581, 10.1093/abbs/gmx046 · doi:10.1093/abbs/gmx046
  43. Dajon, 2019, Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells, OncoImmunology, 8, 10.1080/2162402X.2018.1505174 · DOI
  44. Engel, 2011, The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system, Expert Rev. Clin. Pharmacol., 4, 275, 10.1586/ecp.11.5 · DOI · Paper page
  45. Jia, 2010, Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model, J. Neuroimmunol., 223, 20, 10.1016/j.jneuroim.2010.03.011 · DOI

Cited by

See all 164

Metadata

Authors
Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2020-01
Volume
469
Pages
173-185
ISSN
0304-3835 (ISSN-L)
OpenAlex
W2981211513
Cited by
164
References
5
FWCI
5.13
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
National Science Foundation of China (81572938)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. https://app.cochat.ai/papers/10.1016/j.canlet.2019.10.020
The paper
Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X. (2020). TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Letters. https://doi.org/10.1016/j.canlet.2019.10.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.